Antifibrotic Therapies (e.g., Pirfenidone, Nintedanib)

Type: drug

Status: FDA Approved (for IPF, increasingly used off-label for progressive fibrosing HP)

Developer: Genentech (Pirfenidone), Boehringer Ingelheim (Nintedanib)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026